Sasako Takayoshi, Ueki Kohjiro, Miyake Kana, Okazaki Yukiko, Takeuchi Yasuhiro, Ohashi Yasuo, Noda Mitsuhiko, Kadowaki Takashi
Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Molecular Diabetic Medicine, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan.
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2116-e2128. doi: 10.1210/clinem/dgab013.
To evaluate the effects of an intensified multifactorial intervention and patient characteristics on the incidence of fractures comorbid with type 2 diabetes.
Fracture events were identified and analyzed among adverse events reported in the J-DOIT3 study, a multicenter, open-label, randomized, parallel-group trial that was conducted in Japan, in which patients with type 2 diabetes were randomly assigned to receive conventional therapy for glucose, blood pressure, and lipids (targets: HbA1c < 6.9%, blood pressure <130/80 mm Hg, LDL-cholesterol <120mg/dL) or intensive therapy (HbA1c < 6.2%, blood pressure <120/75 mm Hg, LDL-cholesterol <80mg/dL) (ClinicalTrials.gov registration no. NCT00300976).
The cumulative incidence of fractures did not differ between those receiving conventional therapy and those receiving intensive therapy (hazard ratio (HR) 1.15; 95% CI, 0.91-1.47; P = 0.241). Among the potential risk factors, only history of smoking at baseline was significantly associated with the incidence of fractures in men (HR 1.96; 95% CI, 1.04-3.07; P = 0.038). In contrast, the incidence of fractures in women was associated with the FRAX score [%/10 years] at baseline (HR 1.04; 95% CI, 1.02-1.07; P < 0.001) and administration of pioglitazone at 1 year after randomization (HR 1.59; 95% CI, 1.06-2.38; P = 0.025).
Intensified multifactorial intervention may be implemented without increasing the fracture risk in patients with type 2 diabetes. The fracture risk is elevated in those with a history of smoking in men, whereas it is predicted by the FRAX score and is independently elevated with administration of pioglitazone in women.
评估强化多因素干预及患者特征对2型糖尿病合并骨折发生率的影响。
在日本进行的一项多中心、开放标签、随机、平行组试验J-DOIT3研究报告的不良事件中识别并分析骨折事件,该研究中2型糖尿病患者被随机分配接受血糖、血压和血脂的常规治疗(目标:糖化血红蛋白<6.9%,血压<130/80 mmHg,低密度脂蛋白胆固醇<120mg/dL)或强化治疗(糖化血红蛋白<6.2%,血压<120/75 mmHg,低密度脂蛋白胆固醇<80mg/dL)(ClinicalTrials.gov注册号:NCT00300976)。
接受常规治疗和强化治疗的患者骨折累积发生率无差异(风险比(HR)1.15;95%置信区间,0.91 - 1.47;P = 0.241)。在潜在风险因素中,仅基线吸烟史与男性骨折发生率显著相关(HR 1.96;95%置信区间,1.04 - 3.07;P = 0.038)。相比之下,女性骨折发生率与基线时的FRAX评分[每10年%]相关(HR 1.04;95%置信区间,1.02 - 1.07;P < 0.001)以及随机分组后1年使用吡格列酮有关(HR 1.59;95%置信区间,1.06 - 2.38;P = 0.025)。
在2型糖尿病患者中实施强化多因素干预可能不会增加骨折风险。男性有吸烟史者骨折风险升高,而女性骨折风险可由FRAX评分预测,且使用吡格列酮会使其独立升高。